BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nguyen TT, Trinh NT, Tran HN, Tran HT, Le PQ, Ngo DN, Tran-Van H, Van Vo T, Vong LB, Nagasaki Y. Improving silymarin oral bioavailability using silica-installed redox nanoparticle to suppress inflammatory bowel disease. J Control Release 2021;331:515-24. [PMID: 33616078 DOI: 10.1016/j.jconrel.2020.10.042] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang X, Gu H, Zhang H, Xian J, Li J, Fu C, Zhang C, Zhang J. Oral Core-Shell Nanoparticles Embedded in Hydrogel Microspheres for the Efficient Site-Specific Delivery of Magnolol and Enhanced Antiulcerative Colitis Therapy. ACS Appl Mater Interfaces 2021;13:33948-61. [PMID: 34261306 DOI: 10.1021/acsami.1c09804] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
2 Sandoval-gallegos EM, Ramírez-moreno E, Vargas-mendoza N, Arias-rico J, Estrada-luna D, Cuevas-cancino JJ, Jiménez-sánchez RC, Flores-chávez OR, Baltazar-téllez RM, Morales-gonzález JA. Phytochemicals and Their Possible Mechanisms in Managing COVID-19 and Diabetes. Applied Sciences 2021;11:8163. [DOI: 10.3390/app11178163] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Tian W, Wang H, Zhu Y, Wang Q, Song M, Cao Y, Xiao J. Intervention effects of delivery vehicles on the therapeutic efficacy of 6-gingerol on colitis. Journal of Controlled Release 2022;349:51-66. [DOI: 10.1016/j.jconrel.2022.06.058] [Reference Citation Analysis]
4 Jabeen N, Sohail M, Shah SA, Mahmood A, Khan S, Kashif MUR, Khaliq T. Silymarin nanocrystals-laden chondroitin sulphate-based thermoreversible hydrogels; A promising approach for bioavailability enhancement. Int J Biol Macromol 2022;218:456-72. [PMID: 35872320 DOI: 10.1016/j.ijbiomac.2022.07.114] [Reference Citation Analysis]
5 Tan C, Fan H, Ding J, Han C, Guan Y, Zhu F, Wu H, Liu Y, Zhang W, Hou X, Tan S, Tang Q. ROS-responsive nanoparticles for oral delivery of luteolin and targeted therapy of ulcerative colitis by regulating pathological microenvironment. Materials Today Bio 2022;14:100246. [DOI: 10.1016/j.mtbio.2022.100246] [Reference Citation Analysis]
6 Wang CJ, Byun MJ, Kim S, Park W, Park HH, Kim T, Lee JS, Park CG. Biomaterials as therapeutic drug carriers for inflammatory bowel disease treatment. Journal of Controlled Release 2022. [DOI: 10.1016/j.jconrel.2022.02.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Nguyen-Trinh QN, Trinh KXT, Trinh NT, Vo VT, Li N, Nagasaki Y, Vong LB. A silica-based antioxidant nanoparticle for oral delivery of Camptothecin which reduces intestinal side effects while improving drug efficacy for colon cancer treatment. Acta Biomater 2022;143:459-70. [PMID: 35235866 DOI: 10.1016/j.actbio.2022.02.036] [Reference Citation Analysis]
8 Wu A, Chen C, Lu J, Sun J, Xiao M, Yue X, Zhou P, Zhao S, Zhong G, Huang C, Qu Y, Zhang C. Preparation of Oral Core-Shell Zein Nanoparticles to Improve the Bioavailability of Glycyrrhizic Acid for the Treatment of Ulcerative Colitis. Biomacromolecules 2021. [PMID: 34905341 DOI: 10.1021/acs.biomac.1c01233] [Reference Citation Analysis]
9 Li X, Fang S, Yu Y, Yang H, Rao Y, Hong D, Lu C, Yu M, Lu X, Yu C, Zhao Q. Oral administration of inflammatory microenvironment-responsive carrier-free infliximab nanocomplex for the targeted treatment of inflammatory bowel disease. Chemical Engineering Journal 2022;445:136438. [DOI: 10.1016/j.cej.2022.136438] [Reference Citation Analysis]
10 Koltai T, Fliegel L. Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions. J Evid Based Integr Med 2022;27:2515690X211068826. [PMID: 35018864 DOI: 10.1177/2515690X211068826] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
11 Sun M, Ban W, Ling H, Yu X, He Z, Jiang Q, Sun J. Emerging nanomedicine and prodrug delivery strategies for the treatment of inflammatory bowel disease. Chinese Chemical Letters 2022. [DOI: 10.1016/j.cclet.2022.03.061] [Reference Citation Analysis]
12 Xu C, Chen S, Chen C, Ming Y, Du J, Mu J, Luo F, Huang D, Wang N, Lin Z, Weng Z. Colon-targeted oral nanoparticles based on ROS-scavenging hydroxyethyl starch-curcumin conjugates for efficient inflammatory bowel disease therapy. Int J Pharm 2022;623:121884. [PMID: 35661797 DOI: 10.1016/j.ijpharm.2022.121884] [Reference Citation Analysis]
13 Xiao Q, Li X, Li Y, Wu Z, Xu C, Chen Z, He W. Biological drug and drug delivery-mediated immunotherapy. Acta Pharm Sin B 2021;11:941-60. [PMID: 33996408 DOI: 10.1016/j.apsb.2020.12.018] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 28.0] [Reference Citation Analysis]
14 Le KM, Trinh N, Nguyen VD, Van Nguyen T, Thi Nguyen T, Van Vo T, Tran TQ, Ngo D, Vong LB, Quang DT. Investigating the Anti-Inflammatory Activity of Curcumin-Loaded Silica-Containing Redox Nanoparticles. Journal of Nanomaterials 2021;2021:1-11. [DOI: 10.1155/2021/6655375] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Chen F, Liu Q. Demystifying phytoconstituent-derived nanomedicines in their immunoregulatory and therapeutic roles in inflammatory diseases. Adv Drug Deliv Rev 2022;186:114317. [PMID: 35533788 DOI: 10.1016/j.addr.2022.114317] [Reference Citation Analysis]
16 Turanlı Y, Acartürk F. Preparation and characterization of colon-targeted pH/Time-dependent nanoparticles using anionic and cationic polymethacrylate polymers. Eur J Pharm Sci 2022;171:106122. [PMID: 35007712 DOI: 10.1016/j.ejps.2022.106122] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Liu P, Li Y, Wang R, Ren F, Wang X. Oxidative Stress and Antioxidant Nanotherapeutic Approaches for Inflammatory Bowel Disease. Biomedicines 2022;10:85. [DOI: 10.3390/biomedicines10010085] [Reference Citation Analysis]